Latchmore Associate’s CEO, Hugh Risebrow is active on LinkedIn and Twitter and posts regular articles about a range of healthcare topics, including private healthcare; NHS/ private commercial partnerships; pathology collaboration between NHS Trusts; commercial activities by NHS organisations; market entry strategy for overseas medical device and service providers; and, digital health.
Follow Hugh Risebrow:
-
Community Diagnostic Centre Update
I recently chaired a panel hosted by solictors Browne Jacobson about CDCs. The panel combined service providers such as Alliance Medical, Architects, property advisers and investors, and the NHS. We were given a virtual tour of Alliance’s impressive CDC at Oldham. I struggled to get good data on CDCs for the Diagnostics UK Market Report…
-
Diagnostics in the UK, post Covid
Diagnostics UK Market Report – 2nd Edition – LaingBuisson The second edition of the LaingBuisson UK diagnostics market report was published last month. Excluding Covid, the 2021 market value (including NHS service costs) was c£8.5bn with around 55m diagnostic images and 750m laboratory tests. Covid testing added £1bn to private lab revenues, with very high…
-
NHS data commercialisation
NHS Data Commercialisation seems to be on the agenda again. Sensyne has signed up at least six Trusts, and Google Deep Mind and Amazon are apparently making overtures, along with a raft of smaller niche companies. I am supporting an NHS organisation to think this through, to ensure that there are benefits for patients and the taxpayer…